Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
⏰ React to the Market Faster with Custom, Real-Time News Get Started
RAPT Therapeutics weakness creates a long-term opportunity - UBS
© Reuters. RAPT Therapeutics (RAPT) weakness creates a long-term opportunity - UBS
By Sam Boughedda
RAPT Therapeutics (NASDAQ:RAPT) shares fell more than 25% on Tuesday, but UBS analysts believe the stock's weakness creates a long-term opportunity.
On Tuesday, RAPT reported fourth-quarter financials, and UBS spoke with the company's management after the release.
"New from today's release is topline data from the Ph2B of RPT193 in atopic dermatitis is now guided for mid-24 vs 2H23 previously, with the company citing slower than expected enrollment of patients due to the lack of an expected seasonal uptick. We see this as a meaningful update given investor focus on what had been the upcoming catalyst for '193 this year," wrote the analysts, who maintained a Buy rating and $61 price target on the stock.
The analysts said the firm noted the share price decrease following the results, which they think is "largely due to shifted timing of atopic derm catalyst," but there is no change in their view of the "program's fundamentals and potential opportunity of '193 if successful in atopic derm."
"We continue to see a large opportunity for a safe oral in atopic derm and see '193 as a highly promising agent based on what we've seen so far from Ph1b data (though early)," they added. "We see atopic derm data as a major catalyst for 2024, with significant upside potential in 2H24 if successful. Despite the delay, we have conviction in shares longer-term, with a market cap of ~$920M vs we estimate over $2B potential peak '193 sales if successful. The company ended the year with cash of ~$249M, which it expects to provide runway beyond the 2024 data read into mid-2025."
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.